PT2931265T - Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática - Google Patents

Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática

Info

Publication number
PT2931265T
PT2931265T PT138627807T PT13862780T PT2931265T PT 2931265 T PT2931265 T PT 2931265T PT 138627807 T PT138627807 T PT 138627807T PT 13862780 T PT13862780 T PT 13862780T PT 2931265 T PT2931265 T PT 2931265T
Authority
PT
Portugal
Prior art keywords
axl
inhibition
modified
peptides
signaling
Prior art date
Application number
PT138627807T
Other languages
English (en)
Inventor
Bruno Rankin Erinn
r cochran Jennifer
J Giaccia Amato
Jones Douglas
Kariolis Mihalis
Fuh Katherine
Miao Yu
Hershenson Susan
Original Assignee
Univ Leland Stanford Junior
Aravive Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2931265(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior, Aravive Biologics Inc filed Critical Univ Leland Stanford Junior
Publication of PT2931265T publication Critical patent/PT2931265T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT138627807T 2012-12-14 2013-12-12 Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática PT2931265T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737276P 2012-12-14 2012-12-14

Publications (1)

Publication Number Publication Date
PT2931265T true PT2931265T (pt) 2018-04-16

Family

ID=50934967

Family Applications (2)

Application Number Title Priority Date Filing Date
PT171966625T PT3326622T (pt) 2012-12-14 2013-12-12 Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
PT138627807T PT2931265T (pt) 2012-12-14 2013-12-12 Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT171966625T PT3326622T (pt) 2012-12-14 2013-12-12 Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática

Country Status (12)

Country Link
US (3) US9822347B2 (pt)
EP (2) EP3326622B1 (pt)
JP (2) JP6345690B2 (pt)
AU (3) AU2013359179B2 (pt)
CA (1) CA2894539C (pt)
DK (2) DK2931265T6 (pt)
ES (2) ES2862335T3 (pt)
FI (1) FI2931265T6 (pt)
HK (1) HK1256071A1 (pt)
NO (1) NO3049208T3 (pt)
PT (2) PT3326622T (pt)
WO (1) WO2014093690A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091305A2 (en) * 2010-01-22 2011-07-28 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
WO2013090776A1 (en) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
DK2931265T6 (da) 2012-12-14 2023-05-01 Univ Leland Stanford Junior Modificerede AXL-petider og deres anvendelse til inhibering af AXL-signalering i en antimetastatisk terapi
CA2909669C (en) 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
CA2971406A1 (en) * 2014-12-18 2016-06-23 Aravive Biologics, Inc. Antifibrotic activity of gas6 inhibitor
AU2018359863A1 (en) * 2017-11-04 2020-07-02 Aravive Biologics, Inc Methods of treating metastatic cancers using axl decoy receptors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5538861A (en) 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US20030032102A1 (en) 1997-09-18 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
WO2004108748A2 (en) 2002-09-24 2004-12-16 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
AU2004231036A1 (en) 2003-04-18 2004-10-28 Novartis Ag Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
JP2005278631A (ja) 2004-03-04 2005-10-13 National Institute Of Advanced Industrial & Technology Axlリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
EP1825005B1 (en) 2004-11-24 2015-07-15 The Regents of the University of Colorado, a body corporate Mer diagnostic and therapeutic agents
EP1897940A4 (en) 2005-05-02 2009-04-15 Toray Industries COMPOSITION AND METHOD FOR DIAGNOSING ESOPHAGEAL CANCER AND METASTASIS OF ESOPHAGEAL CANCER
US8168415B2 (en) * 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
JP2010523712A (ja) 2007-04-13 2010-07-15 スーパージェン, インコーポレイテッド 癌または過剰増殖の治療に有用なaxlキナーゼ阻害剤
EP2170395A1 (en) 2007-07-02 2010-04-07 Wyeth LLC Modulators of axl for use in treating bone disorders
US20120230991A1 (en) * 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
MX2011006621A (es) * 2008-12-19 2011-07-12 Novartis Ag Polipeptidos solubles para uso en el tratamiento de trastornos autoinmunes e inflamatorios.
CN102421802B (zh) * 2009-05-11 2014-08-20 U3制药有限公司 人源化的axl抗体
WO2011091305A2 (en) * 2010-01-22 2011-07-28 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
DK2638173T3 (da) 2010-11-08 2019-09-30 Univ Leland Stanford Junior Fusionsproteiner omfattende et manipuleret knottin-peptid og anvendelser deraf
WO2013090776A1 (en) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
DK2931265T6 (da) 2012-12-14 2023-05-01 Univ Leland Stanford Junior Modificerede AXL-petider og deres anvendelse til inhibering af AXL-signalering i en antimetastatisk terapi
US20150315552A1 (en) 2012-12-14 2015-11-05 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL Signaling in Primary Tumor Therapy
WO2015030849A1 (en) * 2013-08-30 2015-03-05 The Board Of Trustees Of The Leland Stanford Junior University High-affinity binding to gas6
CA2971406A1 (en) * 2014-12-18 2016-06-23 Aravive Biologics, Inc. Antifibrotic activity of gas6 inhibitor

Also Published As

Publication number Publication date
JP2016510309A (ja) 2016-04-07
WO2014093690A1 (en) 2014-06-19
EP2931265A4 (en) 2016-08-31
EP3326622A1 (en) 2018-05-30
AU2017272193A1 (en) 2017-12-21
PT3326622T (pt) 2021-04-07
HK1256071A1 (zh) 2019-09-13
EP3326622B1 (en) 2021-01-20
DK2931265T3 (en) 2018-04-16
US20220220458A1 (en) 2022-07-14
EP2931265A1 (en) 2015-10-21
US20150315553A1 (en) 2015-11-05
AU2019210662A1 (en) 2019-08-22
EP2931265B1 (en) 2018-01-31
AU2013359179A1 (en) 2015-07-02
AU2013359179B2 (en) 2017-10-05
FI2931265T6 (fi) 2023-05-23
DK3326622T3 (da) 2021-04-06
NO3049208T3 (pt) 2018-04-14
US20180030422A1 (en) 2018-02-01
ES2862335T3 (es) 2021-10-07
JP6832887B2 (ja) 2021-02-24
ES2665323T7 (es) 2023-06-15
JP2018154641A (ja) 2018-10-04
US11136563B2 (en) 2021-10-05
CA2894539A1 (en) 2014-06-19
JP6345690B2 (ja) 2018-06-20
AU2019210662B2 (en) 2021-07-01
CA2894539C (en) 2021-09-28
DK2931265T6 (da) 2023-05-01
ES2665323T3 (es) 2018-04-25
US9822347B2 (en) 2017-11-21
EP2931265B3 (en) 2023-04-05

Similar Documents

Publication Publication Date Title
HK1245806A1 (zh) 抗轉移療法中axl信號傳導的抑制
HK1256071A1 (zh) 改性axl肽及其在抗轉移治療中抑制axl信號傳導的應用
EP2831001A4 (en) COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
EP2912178A4 (en) SUPER AMPLIFIER AND METHOD FOR USE THEREOF
ZA201307797B (en) Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) Bicyclic heterocycle compounds and their uses in therapy
ZA201405858B (en) Recombinant microorganisms and methods of use thereof
GB201218850D0 (en) Bicyclic heterocycle compounds and their uses in therapy
EP2906700A4 (en) GENETICALLY ENCODED CALCIUM INDICATORS AND METHODS OF USE
GB201218864D0 (en) Bicyclic heterocycle compounds and their uses in therapy
HK1203842A1 (en) Maesa japonica extracts and methods of use
EP2806811A4 (en) VERTEBRAL CONSTRUCTION
HK1204772A1 (en) Aromatic-cationic peptides and uses of same
EP2852397A4 (en) HUWENTOXIN IV VARIANTS AND METHODS OF USE
HK1207953A1 (en) An enhanced therapeutic stimulus system and methods of use
EP2790666A4 (en) MAESA JAPONICA EXTRACTS AND METHOD OF USE THEREOF
HK1209639A1 (en) Gpbp-1 inhibition and its therapeutic use gpbp-1
HK1247087A1 (zh) 草藥補充劑及其使用方法
PL2667880T3 (pl) Oligopeptydy metaloproteinaz i ich zastosowanie terapeutyczne
EP2934543A4 (en) STIMULATION AND INCREASE IN TISSUE REGENERATION
GB201219678D0 (en) Ketone body inhibitors and uses thereof
EP2744786A4 (en) SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
HK1206977A1 (en) Aromatic-cationic peptides and uses of same
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
EP2817004A4 (en) BOUVARDIN DERIVATIVES AND THEIR THERAPEUTIC USES